MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
21.09
-0.30
-1.40%
Closed 18:06 06/12 EDT
OPEN
21.49
PREV CLOSE
21.39
HIGH
21.55
LOW
21.05
VOLUME
753.94K
TURNOVER
0
52 WEEK HIGH
28.35
52 WEEK LOW
19.69
MARKET CAP
3.61B
P/E (TTM)
9.64
1D
5D
1M
3M
1Y
5Y
1D
A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Shares Show Mixed Recent Momentum
Simply Wall St · 5d ago
Weekly Report: what happened at ACAD last week (0601-0605)?
Weekly Report · 6d ago
Weekly Report: what happened at ACAD last week (0525-0529)?
Weekly Report · 06/01 09:32
Acadia Shareholders Approve Directors, Executive Pay and Equity Plan
TipRanks · 05/29 21:04
ACADIA Pharmaceuticals shareholders approved 5.21 million-share increase to 2024 equity plan
PUBT · 05/29 20:07
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans
NASDAQ · 05/27 12:48
Weekly Report: what happened at ACAD last week (0518-0522)?
Weekly Report · 05/25 09:33
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (CRDF), ACADIA Pharmaceuticals (ACAD) and Immunic (IMUX)
TipRanks · 05/22 13:30
More
About ACAD
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.

Webull offers ACADIA Pharmaceuticals Inc stock information, including NASDAQ: ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.